Natera, Inc. (NTRA) Stock Analysis
Breakout setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $220.35, but acceptable to hold if already in. Reasons: Concentration risk — Product: Panorama NIPT, Horizon, and Signatera (majority of revenue); Concentration risk — Counterparty: DNAnexus (sole cloud platform for algorithms).
Natera is a diagnostics company commercializing cfDNA-based tests for oncology (Signatera MRD), women's health (Panorama NIPT, Horizon carrier screening), and organ health (Prospera transplant rejection). Revenue reached $2,306.1M in 2025 ($2,295.8M product revenue), processing... Read more
Hold if already holding. Not a fresh buy at $220.35, but acceptable to hold if already in. Reasons: Concentration risk — Product: Panorama NIPT, Horizon, and Signatera (majority of revenue); Concentration risk — Counterparty: DNAnexus (sole cloud platform for algorithms). Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Mixed signals. Hold existing position. Score 5.5/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-12Recent Developments — Natera, Inc.
Latest news
- NEWS Natera shares slide as investors weigh near-term sentiment headwinds ahead of upcoming earnings - Quiver Quantitative — Quiver Quantitative negative
- NEWS Natera, Inc. (NASDAQ:NTRA) Short Interest Down 22.5% in April - MarketBeat — MarketBeat negative
- NEWS Should You Be Bullish on Natera (NTRA)? - Yahoo Finance — Yahoo Finance positive
- NEWS What To Expect From Natera’s (NTRA) Q4 Earnings - StockStory — StockStory neutral
- NEWS Natera president John Fesko sells $59,992 of NTRA shares - Investing.com — Investing.com negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPanorama NIPT, Horizon, and Signatera (majority of revenue)10-K Item 1A: 'the significant majority of our revenues are derived from sales of our Panorama NIPT, our Horizon carrier screening, or HCS, test, and our Signatera test'
- HIGHcounterpartyDNAnexus (sole cloud platform for algorithms)10-K Item 1: 'We do not have any backup cloud platform, server or other means to host our algorithms, and may be unable to find and implement an alternative platform that is satisfactory for our needs on commercially reasonable terms, in a timely manner, or at all'
Material Events(8-K, last 90d)
- 2026-04-01Item 5.02LOWEric Rubin appointed as Class I director to the Board effective March 26, 2026; Board expanded from ten to eleven members. Dr. Rubin joins Nominating, Corporate Governance and Compliance Committee. No arrangement cited for selection.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $220.35, but acceptable to hold if already in. Reasons: Concentration risk — Product: Panorama NIPT, Horizon, and Signatera (majority of revenue); Concentration risk — Counterparty: DNAnexus (sole cloud platform for algorithms). Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Mixed signals. Hold existing position. Target $233.34 (+5.9%), stop $203.88 (−8.1%), A.R:R 0.4:1. Score 5.5/10, moderate confidence.
Take-profit target: $233.34 (+6.4% upside). Target $233.34 (+5.9%), stop $203.88 (−8.1%), A.R:R 0.4:1. Stop-loss: $203.88.
Concentration risk — Product: Panorama NIPT, Horizon, and Signatera (majority of revenue); Concentration risk — Counterparty: DNAnexus (sole cloud platform for algorithms); Thin upside margin: 6.4%.
Natera, Inc. trades at a P/E of N/A (forward -732.9). TrendMatrix value score: 4.3/10. Verdict: Hold.
27 analysts cover NTRA with a consensus score of 4.3/5. Average price target: $259.
What does Natera, Inc. do?Natera is a diagnostics company commercializing cfDNA-based tests for oncology (Signatera MRD), women's health...
Natera is a diagnostics company commercializing cfDNA-based tests for oncology (Signatera MRD), women's health (Panorama NIPT, Horizon carrier screening), and organ health (Prospera transplant rejection). Revenue reached $2,306.1M in 2025 ($2,295.8M product revenue), processing approximately 3.5 million tests. The company markets tests through a direct U.S. sales force and 100+ international lab/distribution partners.